1. Market Research
  2. > Pharmaceutical Market Trends
Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028

Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028

  • April 2022
  • 240 pages
  • ID: 6251536
  • Format: PDF
  • Kuick Research

Summary

Table of Contents

Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights:

• Global Bcr-Abl Inhibitor Market Opportunity > USD 8 Billion
• Approved Bcr-Abl Inhibitor Drugs: 8 Drugs
• Global Bcr-Abl Inhibitor Market Regional Analysis & Forecast Till 2028
• Bcr-Abl Inhibitor Drug Market Past Sales & Future Forecast Till 2028
• Market Analysis By First, Second & Third Generation Approved drugs
• Bcr-Abl Inhibitor Drug Prices, Dosage & Patent Insight
• Global Bcr-Abl Inhibitor Drug clinical Trials Insight by Indication ,Company, County & Phase

Chronic myeloid leukemia is a myeloproliferative disorder which is characterized by the abnormal granulocyte cells proliferation. Since last two decades, there have been significant advances in the management of chronic myeloid leukemia. New drug class that has transformed the treatment of CML includes tyrosine kinases (TKIs) or BCR-ABL inhibitors. The BCR-ABL targets are downstream pathways including RAS, PI3K/AKT, and JAK/STAT that address the transformation of healthy cells toward neoplastic cells responsible for pathogenesis of chronic myeloid leukemia, thus making it potential target for the drug development.

Imatinib was first Bcr-Abl inhibitor, which was approved by FDA in 2001 as first-line therapy for chronic myeloid leukemia. Unfortunately, the appearance of resistance phenomena required the development of a second generation of Bcr-Abl inhibitors. Currently three 2nd generation drugs including Nilotinib, Dasatinib and Bosulitinib whereas one 3rd generation drug, Ponatinib has been approved for the management of CML which have shown enhanced efficacy in comparison to already approved drugs. In addition, Olverembatinib which is third generation inhibitor developed by Ascentage Pharma has gained entry into China. The promising response of Bcr-Abl inhibitors in the market has propelled the further research and development activities in this domain.

Companies operating in the Bcr-Abl tyrosine kinase inhibitors industry are focusing on increasing their geographic presence by means of strategic acquisitions and collaborations with leading players and increasing FDA approvals of therapeutic drugs in their respective domains and geographies. For instance, Ascentage Pharma also announced a multifaced strategic collaboration with Innovent Biologics. This collaboration includes the joint clinical development and commercialization of Olverembatinib in China. Ascentage Pharma has recently announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has granted approval to Olverembatinib (HQP1351), for the treatment of patients with chronic phase CML resistant and/intolerant to first and second generation TKI.

US has been dominating the global Bcr-Abl inhibitor market driven by more than 100 clinical trials which are evaluating the role of novel Bcr-Abl inhibitors as monotherapy or combinational therapy in wide range of therapeutic indications. Further, the governments regulatory are also increasingly granting special designations such as orphan drug, breakthrough therapy, and others which promote the research and development. For instance in 2020, US FDA granted HQP1351 orphan drug designation for the treatment of patients with chronic myeloid leukemia. HQP1351 is a novel, orally active, potent third generation Bcr-Abl inhibitor which is designed to target Bcr-Abl mutants, including T3151.

As per our report findings, the global Bcr-Abl inhibitor market will surpass US$ 8 Billion by 2028. The major factor attributing to the growth of the market is increasing prevalence of chronic myeloid leukemia (CML). Furthermore, growing investments in research and development programs by biotechnology and pharmaceutical companies are also boosting the market growth. The development of favorable reimbursement policies and introduction of generics in the market will also drive the growth of market. The key companies in global Bcr-Abl inhibitor market are Ascentage Pharma, Incyte Pharmaceuticals, Novartis, Bristol Meyer Squibb, Ariad Pharmaceuticals, and others.

Our report provides in-depth analysis on the available Bcr-Abl inhibitors in the global market along with their commercial information. In addition, insights into ongoing clinical trials and key drugs in research and development are also included in the report. The report also provides profiles of leading players operating in the global tyrosine kinase inhibitors market. The report includes detailed analysis on market dynamics, market estimation and forecast for the period of 2022 to 2028. The report segments market on the basis of drug type and geographies.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Single Use Assemblies Market Research Report by Product, Solution, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • $ 3949
  • July 2022
  • 256 pages

Single Use Assemblies Market Research Report by Product (Bag Assemblies, Bottle Assemblies, and Filtration Assemblies), Solution, Application, End User, Region (Americas, Asia-Pacific, and Europe, Middle ...

  • World
  • Pharmaceutical
  • Marketing Research
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on